From the Departments of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center, and the University of Pittsburgh Medical Center, Philadelphia and Pittsburgh.
J Clin Psychiatry. 2012 Jul;73(7):e24. doi: 10.4088/JCP.11096tx4c.
Monoamine oxidase inhibitors (MAOIs) have proven efficacy for treating depression, particularly in patients with atypical depression, high levels of anxiety, anergic bipolar depression, and treatment-resistant depression. However, MAOIs are not supported as first-line treatments due to safety and tolerability concerns and the need for dietary restrictions; instead, current guidelines recommend MAOIs as third-, fourth-, or fifth-line treatments. However, a newer, transdermal MAOI formulation limits the need for dietary restrictions and has fewer sexual and metabolic effects than some of the newer antidepressants.
单胺氧化酶抑制剂 (MAOIs) 已被证明对治疗抑郁症有效，尤其是对非典型抑郁症、焦虑程度高、无反应性双相抑郁症和治疗抵抗性抑郁症患者。然而，由于安全性和耐受性问题以及饮食限制的需要，MAOIs 并未被支持作为一线治疗药物；相反，目前的指南建议将 MAOIs 作为三线、四线或五线治疗药物。然而，一种新的、透皮 MAOI 制剂限制了对饮食限制的需求，并且与一些较新的抗抑郁药相比，其对性功能和代谢的影响较小。
